Vitality Watch

Dossier clinicaltrials trial early 16-jun-2026
Small or early-phase human trial or pilot study

Using Light Therapy for Mild Cognitive Impairment

Key claim: A 12-week sham-controlled clinical trial is testing whether daily 20-minute transcranial near-infrared photobiomodulation improves cognitive function, neurovascular coupling, and markers of inflammation and oxidative stress in people with mild cognitive impairment.

Abstract

The goal of this clinical trial is to test whether transcranial photobiomodulation (tPBM), a non-invasive brain stimulation technique using near-infrared light, can improve brain blood flow regulation (neurovascular coupling) and cognitive function in people with mild cognitive impairment (MCI). The main questions it aims to answer are:

  • Does tPBM enhance cognitive function and cerebral hemodynamic responses during memory and finger tapping tasks?
  • Does tPBM reduce oxidative stress, inflammation, and mitigate brain cell damage?
  • Is cognitive improvement linked to amyloid status, greater cerebral hemodynamic response, and lower levels of brain inflammation and oxidative stress? Researchers will compare an active tPBM treatment arm to a sham treatment arm to see if tPBM leads to measurable improvements in brain activity and cognitive function compared to no active stimulation.

Participants will:

  • Receive a 20-minute-long active tPBM or sham stimulation session once per day, 6 times per week, for 12 weeks.
  • Complete questionnaires and an iPad-based cognitive testing protocol.
  • Complete memory and motor tasks while their brain activity is measured using non-invasive techniques: simultaneous functional near-infrared spectroscopy (fNIRS) and electroencephalography (EEG). Dynamic analysis of the vessels in the eye will also be performed based on eligibility. Transcranial Doppler (TCD) flowmetry is optionally performed.
  • Provide blood samples to test for biomarkers of inflammation, oxidative stress, and brain cell damage.

Why this matters

Transcranial photobiomodulation is spreading in the biohacking market (helmets, in-clinic panels) largely on mechanism and small pilots; a sham-controlled MCI trial with neurovascular and inflammatory readouts is the kind of test that would move the claim from mechanism-plausible toward human-RCT territory. Until the readout lands, the trend momentum still outruns the evidence, and the trial’s design — not its outcome — is what’s newsworthy.

Source

Link

Briefing card

Using Light Therapy for Mild Cognitive Impairment
Stage: trial early · clinicaltrials · 16-jun-2026

If you're using a red-light or NIR head device for cognitive concerns, this is a protocol registration, not a result — no efficacy data has been reported yet.

A 12-week sham-controlled clinical trial is testing whether daily 20-minute transcranial near-infrared photobiomodulation improves cognitive function, neurovascular coupling, and markers of inflammation and oxidative stress in people with mild cognitive impairment.

Cross-references (0)

None recorded — doctrine links and citations appear here as scans and citation sweeps find them.

External: nct:NCT07651787

build build 880 · 2bcef25 · 2026-11-18